Aspirin or low-molecular weight heparin for thromboprophylaxis after a fracture? That is the question

Published: 17 May 2023
Abstract Views: 582
PDF: 304
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

Not available

Dimensions

Altmetric

PlumX Metrics

Downloads

Download data is not yet available.

Citations

O'Toole RV, Stein DM, O'Hara NN, et al. Aspirin or low-molecular-weight heparin for thromboprophylaxis after a fracture. N Engl J Med 2023;388:203-13. DOI: https://doi.org/10.1056/NEJMoa2205973
Mohr DN, Silverstein MD, Murtaugh PA, Harrison JM. Prophylactic agents for venous thrombosis in elective hip surgery. Meta-analysis of studies using venographic assessment. Arch Intern Med 1993;153:2221-8. DOI: https://doi.org/10.1001/archinte.153.19.2221
No authors listed. Prevention of pulmonary embolism and deep vein thrombosis with low dose aspirin: Pulmonary Embolism Prevention (PEP) trial. Lancet 2000;355:1295-302. DOI: https://doi.org/10.1016/S0140-6736(00)02110-3
Falck-Ytter Y, Francis CW, Johanson NA, et al. Prevention of VTE in orthopedic surgery patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012;141:e278-325S. DOI: https://doi.org/10.1378/chest.141.5.1369b
Anderson DR, Morgano GP, Bennett C, et al. American Society of Hematology 2019 guidelines for management of venous thromboembolism: prevention of venous thromboembolism in surgical hospitalized patients. Blood Adv 2019;3:3898-944. DOI: https://doi.org/10.1182/bloodadvances.2019000975
Anderson DR, Dunbar MJ, Bohm ER, et al. Aspirin versus low-molecular-weight heparin for extended venous thromboembolism prophylaxis after total hip arthroplasty: a randomized trial. Ann Intern Med 2013;158:800-6. DOI: https://doi.org/10.7326/0003-4819-158-11-201306040-00004
Anderson DR, Dunbar M, Murnaghan J, et al. Aspirin or rivaroxaban for VTE prophylaxis after hip or knee arthroplasty. N Engl J Med 2018;378:699-70. DOI: https://doi.org/10.1056/NEJMoa1712746
Quinlan DJ, Eikelboom JW, Dahl OE, et al. Association between asymptomatic deep-vein thrombosis detected by venography and symptomatic venous thromboembolism in patients undergoing elective hip or knee surgery. J Thromb Haemost 2007;5:1438-43. DOI: https://doi.org/10.1111/j.1538-7836.2007.02571.x
Ageno W, Bertù L, Bucherini E, et al. Rivaroxaban treatment for six weeks versus three months in patients with symptomatic isolated distal deep vein thrombosis: randomised controlled trial. BMJ 2022;379:e072623. DOI: https://doi.org/10.1136/bmj-2022-072623
Turner BRH, Thapar A, Jasionowska S, et al. Systematic review and meta-analysis of the pooled rate of post-thrombotic syndrome after isolated distal deep venous thrombosis. Eur J Vasc Endovasc Surg 2023;65:291-7. DOI: https://doi.org/10.1016/j.ejvs.2022.10.018
Sidhu VS, Kelly TL, Pratt N, et al. Effect of aspirin vs enoxaparin on symptomatic venous thromboembolism in patients undergoing hip or knee arthroplasty: the CRISTAL randomized trial. JAMA 2022;328:719-27. DOI: https://doi.org/10.1001/jama.2022.13416
Vergallo R, Patrono C. Aspirin for venous thromboprophylaxis after fracture: ready for prime time? Eur Heart J 2023;44:1299-300. DOI: https://doi.org/10.1093/eurheartj/ehad098
Samama CM, Laporte S, Rosencher N, et al. Rivaroxaban or enoxaparin in nonmajor orthopedic surgery. N Engl J Med 2020;382:1916-25. DOI: https://doi.org/10.1056/NEJMoa1913808

How to Cite

Camporese, G., Prandoni, P., & Ageno, W. (2023). Aspirin or low-molecular weight heparin for thromboprophylaxis after a fracture? That is the question. Bleeding, Thrombosis and Vascular Biology, 2(2). https://doi.org/10.4081/btvb.2023.82